Five medications are now approved for treating non-syndromic obesity in children, with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination phentermine/topiramate showing the greatest efficacy in adolescents. Emerging data suggest GLP-1 RAs may improve blood pressure and kidney outcomes beyond their weight loss effects, though pediatric evidence remains limited. This represents a significant shift in pediatric obesity treatment philosophy. The traditional reliance on lifestyle interventions alone has proven insufficient due to access and sustainability barriers, necessitating pharmacological support for many young patients. The cardiovascular-kidney-metabolic benefits of GLP-1 RAs could be transformative for preventing adult diseases that originate in childhood obesity. However, substantial limitations persist: lack of long-term safety data in developing bodies, unknown durability of weight loss after discontinuation, and significant cost barriers that may exacerbate health inequities. The emphasis on 'preclinical obesity' - identifying organ dysfunction before clinical manifestation - suggests a proactive medical approach that could reshape how we prevent chronic diseases. While promising, the field needs robust pediatric trials to establish optimal dosing, duration, and long-term effects before widespread adoption.